Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-assisted psychotherapy for treatment-resistant depression
ACTRN12624000040561Phase 4Recruiting
- Sponsor
- Dr and A/ Professor Ranil Gunewardene
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of psilocybin in treatment-resistant depression (TRD), sponsored by Dr and A/ Professor Ranil Gunewardene. Primary endpoint: Change in clinician-rated depression severity. Started Dec 2023; status: recruiting.
02
Drugs
psilocybin
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on ACTRN12624000040561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000040561.